Skip to Content

No Altered Risk of IBD Associated with the Overall Use of GLP-1 Based Therapies

In the following MEDtalk, Heidi Søgaard Christensen from PREDICT, Copenhagen, discusses the initial study exploring the impact of GLP-1 based therapies on the likelihood of individuals with type 2-diabetes developing IBD. The investigation was prompted by a prior study that linked the use of DPP4i to a higher risk of inflammatory bowel disease (IBD), although two other studies found no significant changes in risk.

Heidi Søgaard Christensen

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top